UA106457C2 - Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы - Google Patents
Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазыInfo
- Publication number
- UA106457C2 UA106457C2 UAA201312419A UAA201312419A UA106457C2 UA 106457 C2 UA106457 C2 UA 106457C2 UA A201312419 A UAA201312419 A UA A201312419A UA A201312419 A UAA201312419 A UA A201312419A UA 106457 C2 UA106457 C2 UA 106457C2
- Authority
- UA
- Ukraine
- Prior art keywords
- hmg
- omega
- inhibitor
- fatty acid
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к пероральной комплексной композиции, содержащей сложные эфиры жирной кислоты омега-3 и ингибитор HMG-CoA редуктазы, которая может эффективно повышать уровень сывороточного ЛПВП, при этом снижая уровни сывороточного ЛПНП и ТГ, и может быть использована для лечения гиперлипидемии благодаря хорошей скорости растворения лекарственного средства и устойчивости при хранении, при отсутствии свойства замедленного высвобождения даже после 6 месяцев ускоренного хранения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110025940 | 2011-03-23 | ||
PCT/KR2012/002134 WO2012128587A2 (en) | 2011-03-23 | 2012-03-23 | Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
UA106457C2 true UA106457C2 (ru) | 2014-08-26 |
Family
ID=47280992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201312419A UA106457C2 (ru) | 2011-03-23 | 2012-03-23 | Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы |
Country Status (31)
Country | Link |
---|---|
US (1) | US20140010872A1 (ru) |
EP (1) | EP2688558B1 (ru) |
JP (1) | JP2014508802A (ru) |
KR (1) | KR101310710B1 (ru) |
CN (1) | CN103442699B (ru) |
AR (1) | AR085547A1 (ru) |
AU (1) | AU2012231944B2 (ru) |
BR (1) | BR112013023819A2 (ru) |
CA (1) | CA2830342C (ru) |
CL (1) | CL2013002611A1 (ru) |
CO (1) | CO6801750A2 (ru) |
CR (1) | CR20130491A (ru) |
DO (1) | DOP2013000210A (ru) |
EA (1) | EA023405B1 (ru) |
EC (1) | ECSP13012959A (ru) |
ES (1) | ES2550392T3 (ru) |
GT (1) | GT201300217A (ru) |
HK (1) | HK1189173A1 (ru) |
IL (1) | IL228516A (ru) |
JO (1) | JO3071B1 (ru) |
MA (1) | MA35042B1 (ru) |
MX (1) | MX343097B (ru) |
MY (1) | MY157200A (ru) |
NI (1) | NI201300086A (ru) |
PE (1) | PE20140640A1 (ru) |
SA (1) | SA112330374B1 (ru) |
SG (1) | SG193491A1 (ru) |
TW (1) | TWI571271B (ru) |
UA (1) | UA106457C2 (ru) |
WO (1) | WO2012128587A2 (ru) |
ZA (1) | ZA201307871B (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) * | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
GB2512098A (en) * | 2013-03-20 | 2014-09-24 | Roly Bufton | An oral dosage form |
KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
WO2014182003A1 (en) * | 2013-05-06 | 2014-11-13 | Hanmi Pharm. Co., Ltd. | Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
EP3150201B1 (en) * | 2014-06-30 | 2020-02-19 | Hanmi Pharm. Co., Ltd. | Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation |
WO2016003180A1 (ko) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법 |
WO2016003181A1 (ko) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | 활성성분-함유 필름 코팅층을 포함하는 복합제제 |
TWI525110B (zh) | 2014-12-24 | 2016-03-11 | 財團法人工業技術研究院 | 聚合物、及包含其之醫藥組合物 |
KR101950907B1 (ko) * | 2016-02-05 | 2019-02-21 | 한국유나이티드제약 주식회사 | 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2017171484A1 (ko) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
ITRM20040395A1 (it) * | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
US20070191467A1 (en) * | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
CA2589654C (en) * | 2004-12-06 | 2016-02-16 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
BRPI0607569A2 (pt) * | 2005-03-08 | 2009-09-15 | Reliant Pharmaceuticals Inc | composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária |
AU2006275784A1 (en) * | 2005-07-28 | 2007-02-08 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
WO2007103557A2 (en) * | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US20090041839A1 (en) * | 2007-05-23 | 2009-02-12 | Beasley Martin W | Pharmaceutical compositions for the treatment of pain |
JP5421126B2 (ja) * | 2008-01-10 | 2014-02-19 | 武田薬品工業株式会社 | カプセル製剤 |
CN101945646A (zh) * | 2008-02-13 | 2011-01-12 | 拜耳先灵医药股份有限公司 | 含雌二醇的药物递送系统 |
KR20090091085A (ko) * | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 방출성이 제어된 약제학적 제제 |
KR20090114190A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 방출성이 제어된 HMG―CoA 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물 |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
-
2011
- 2011-04-29 KR KR1020110041168A patent/KR101310710B1/ko active IP Right Grant
-
2012
- 2012-03-21 JO JOP/2012/0059A patent/JO3071B1/ar active
- 2012-03-22 TW TW101109888A patent/TWI571271B/zh not_active IP Right Cessation
- 2012-03-23 AU AU2012231944A patent/AU2012231944B2/en not_active Ceased
- 2012-03-23 CN CN201280014233.6A patent/CN103442699B/zh not_active Expired - Fee Related
- 2012-03-23 EP EP12760271.2A patent/EP2688558B1/en not_active Not-in-force
- 2012-03-23 MY MYPI2013003396A patent/MY157200A/en unknown
- 2012-03-23 MA MA36333A patent/MA35042B1/fr unknown
- 2012-03-23 ES ES12760271.2T patent/ES2550392T3/es active Active
- 2012-03-23 EA EA201391372A patent/EA023405B1/ru not_active IP Right Cessation
- 2012-03-23 US US14/006,191 patent/US20140010872A1/en not_active Abandoned
- 2012-03-23 CA CA2830342A patent/CA2830342C/en not_active Expired - Fee Related
- 2012-03-23 WO PCT/KR2012/002134 patent/WO2012128587A2/en active Application Filing
- 2012-03-23 AR ARP120100974A patent/AR085547A1/es unknown
- 2012-03-23 JP JP2014501011A patent/JP2014508802A/ja active Pending
- 2012-03-23 BR BR112013023819A patent/BR112013023819A2/pt not_active IP Right Cessation
- 2012-03-23 PE PE2013002066A patent/PE20140640A1/es not_active Application Discontinuation
- 2012-03-23 MX MX2013010753A patent/MX343097B/es active IP Right Grant
- 2012-03-23 SG SG2013069695A patent/SG193491A1/en unknown
- 2012-03-23 UA UAA201312419A patent/UA106457C2/ru unknown
- 2012-03-24 SA SA112330374A patent/SA112330374B1/ar unknown
-
2013
- 2013-09-11 CL CL2013002611A patent/CL2013002611A1/es unknown
- 2013-09-17 IL IL228516A patent/IL228516A/en active IP Right Grant
- 2013-09-19 GT GT201300217A patent/GT201300217A/es unknown
- 2013-09-20 DO DO2013000210A patent/DOP2013000210A/es unknown
- 2013-09-20 NI NI201300086A patent/NI201300086A/es unknown
- 2013-09-30 CR CR20130491A patent/CR20130491A/es unknown
- 2013-10-09 EC ECSP13012959 patent/ECSP13012959A/es unknown
- 2013-10-18 CO CO13247569A patent/CO6801750A2/es not_active Application Discontinuation
- 2013-10-22 ZA ZA2013/07871A patent/ZA201307871B/en unknown
-
2014
- 2014-03-09 HK HK14102333.6A patent/HK1189173A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA106457C2 (ru) | Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы | |
EP2844257A4 (en) | Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE | |
SV2018005621A (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
IN2013MN00501A (ru) | ||
EP2560633B8 (en) | Intravenous omega-3 fatty acid compositions & method of use | |
ZA201203993B (en) | Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds | |
PH12015502706A1 (en) | Oral formulation for the treatment of cardiovascular diseases | |
SA112340005B1 (ar) | صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa | |
WO2011096665A3 (en) | Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor | |
EP2428202A3 (en) | Orally disintegrating compositions | |
EP2727591A3 (en) | Stable pharmaceutical compositions containing cefaclor and clavulanic acid | |
MA35160B1 (fr) | Inhibiteur du virus de l'hépatite c | |
TH133918B (th) | องค์ประกอบเชิงซ้อนสำหรับช่องปากซึ่งประกอบรวมด้วยเอสเทอร์ของกรดไขมันโอเมกา-3 และตัวยับยั้ง hmg-coa รีดักเทส |